How to Decrease Serotonin in the Gut

Lowering serotonin in the gut comes down to three broad strategies: reducing how much gets made, blocking its action on intestinal receptors, or speeding up the way the body clears it. More than 90 percent of your body’s serotonin is produced in the intestine, not the brain, and excess gut serotonin drives real problems like chronic diarrhea, visceral pain, and intestinal inflammation. The approaches range from prescription drugs that shut down the enzyme responsible for production to dietary shifts and microbiome changes that dial it back more gently.

When Gut Serotonin Becomes a Problem

Most people hear “serotonin” and think mood, but the gut version operates almost independently from the brain version. In the intestine, serotonin controls motility, secretion, and pain signaling. When the system works well, food moves through at a reasonable pace and you barely notice. When serotonin levels run too high, the intestine speeds up, secretes too much fluid, and pain thresholds drop.

The most common condition linked to excess gut serotonin is diarrhea-predominant irritable bowel syndrome (IBS-D). Patients with this subtype have increased serotonin production and availability in the gut, which ramps up motility and causes both diarrhea and abdominal pain.¹ In one mouse model of IBS-D, transferring gut contents from IBS-D patients into mice increased mucosal serotonin and cut serotonin transporter expression by roughly half, producing the same diarrhea and pain sensitivity seen in humans.²

Carcinoid syndrome is a rarer but more dramatic example. Neuroendocrine tumors can flood the body with serotonin, causing severe flushing, wheezing, and relentless watery diarrhea. Inflammatory bowel disease also features elevated gut serotonin, where the molecule appears to actively worsen inflammation rather than just tagging along for the ride. And in post-infectious IBS, the enterochromaffin cells that produce serotonin can become hyperplastic, meaning there are simply more of them pumping out the molecule than there should be.³

How Gut Serotonin Gets Made

Specialized cells called enterochromaffin cells, scattered throughout the lining of the intestine, are the main serotonin factories. They take tryptophan, an amino acid from your diet, and convert it into serotonin using an enzyme called tryptophan hydroxylase 1, or TPH1. This enzyme is the bottleneck. If TPH1 activity goes up, serotonin production goes up. Almost every strategy for reducing gut serotonin works by targeting some part of this chain: the tryptophan supply, the enzyme itself, the signals that tell the enzyme to ramp up, or the clearance system that mops serotonin up after it’s released.

Once serotonin is secreted, it acts on receptors along the gut wall and on nerve endings. The signal gets terminated when a protein called the serotonin reuptake transporter (SERT) pulls serotonin back into cells, effectively clearing it from the scene. When SERT doesn’t work well, serotonin lingers and keeps firing. Mice lacking SERT entirely develop worse intestinal inflammation when exposed to chemical irritants, showing that clearance is just as important as production.⁴

Prescription Drugs That Block Serotonin Production

The most direct pharmaceutical approach is to inhibit TPH1 itself. Telotristat ethyl (sold as Xermelo) does exactly this. It was developed for carcinoid syndrome, where tumors cause dangerously high serotonin levels, and it reduces diarrhea by cutting off the serotonin supply at the enzymatic source.⁵ The drug works peripherally, meaning it targets gut serotonin without crossing into the brain, so it doesn’t interfere with mood-related serotonin signaling.

Research has pushed beyond carcinoid syndrome. In animal models of inflammatory bowel disease, blocking peripheral serotonin synthesis with telotristat reduced both the onset and severity of colitis.⁶ A separate study using related TPH inhibitors found that reducing enterochromaffin cell serotonin lowered the expression of inflammation-related genes by fourfold or more for about a quarter of the genes tested, without affecting the enteric nervous system or normal gut motility.⁷ That last point matters: these drugs specifically target the mucosal serotonin made by enterochromaffin cells while leaving the serotonin used by gut nerves for normal peristalsis intact.

Telotristat is currently approved only for carcinoid syndrome diarrhea that isn’t controlled by somatostatin analogs alone. Its use for IBD or IBS-D remains investigational, but the animal data make a compelling case that peripheral TPH1 inhibition could eventually become a broader tool.

Blocking Serotonin’s Effects Without Reducing Levels

You don’t always need to reduce the amount of serotonin in the gut if you can block the receptors it acts on. The 5-HT3 receptor is the main target here. When serotonin binds to it, the gut speeds up, secretes more fluid, and pain sensitivity increases. Blocking that receptor slows things down.

5-HT3 receptor antagonists like ondansetron (better known as an anti-nausea drug) and alosetron have shown value for diarrhea-predominant IBS. Evidence from both animal and human studies supports the idea that blocking 5-HT3 receptors reduces gut motility, improves fluid absorption, and raises the pain threshold for visceral discomfort.⁸ In the IBS-D mouse model mentioned earlier, ondansetron prevented the diarrhea, excess fecal water, and heightened pain responses caused by transplanted IBS-D gut contents.²

This approach is a workaround rather than a root-cause fix: serotonin levels stay high, but its downstream effects get blunted. For many IBS-D patients, that’s enough to provide meaningful relief. Alosetron was restricted in prescribing after rare cases of severe constipation and ischemic colitis, but ondansetron has a long safety track record and is used off-label for IBS-D with increasing frequency.

What the Microbiome Has to Do With It

Your gut bacteria are not passive bystanders in serotonin production. Indigenous spore-forming bacteria promote serotonin biosynthesis from enterochromaffin cells, supplying serotonin to the mucosa, the gut lumen, and even circulating blood platelets.⁹ One key mechanism involves short-chain fatty acids (SCFAs), which are produced when gut microbes ferment dietary fiber. SCFAs promote transcription of TPH1 in enterochromaffin cells, effectively telling those cells to make more serotonin.¹⁰

This creates a counterintuitive situation. Fiber is generally promoted as good for gut health, and the SCFAs it generates are anti-inflammatory in many contexts. But those same SCFAs also drive serotonin production. If your problem is specifically excess gut serotonin, more fiber isn’t automatically better. The relationship is context-dependent and not yet fully mapped in humans, but it’s worth knowing that “gut-healthy” interventions don’t always reduce serotonin.

On the other hand, certain probiotic strains may help. In a chronic stress rat model, probiotic treatment showed a tendency to reduce colonic serotonin while redistributing it toward the brain, where it could help with mood. The effect was modest but consistent with the idea that shifting microbial composition can alter where serotonin ends up in the body. Additionally, the microbiome’s influence on SERT expression is emerging as another lever. The IBS-D microbiota study mentioned earlier found that specific gut microbial communities could suppress SERT, leading to serotonin buildup. Reshaping those communities could, in theory, restore normal clearance.²

Diet, Protein Sources, and Plant Compounds

Because serotonin is made from dietary tryptophan, what you eat can shift gut serotonin levels in unexpected ways. A mouse study comparing different protein sources found that the type of protein mattered more than you might expect. Processed meat protein (from emulsion-type sausage) and cooked pork protein both increased gut serotonin levels and boosted TPH1 expression. Soy protein, by contrast, actually decreased serotonin content in the gut despite increasing TPH1 expression, because it also reduced the activity of the enzyme that breaks serotonin down (MAO-A), leading to a different metabolic profile overall.¹¹ These results highlight that the relationship between diet and gut serotonin isn’t a simple matter of eating less tryptophan. The microbial communities that different foods support, and the way those microbes process tryptophan, matter just as much.

Plant-derived compounds are another area of active research. Quercetin, a flavonoid found in onions, apples, and berries, has been tested in rat models of post-inflammatory IBS, where it reduced serotonin availability and attenuated visceral hypersensitivity.³ Tea polyphenols are also being investigated for their interactions with the gut microbiota and potential influence on intestinal serotonin homeostasis, though this work is still in early stages and the mechanisms remain speculative. The general pattern across these studies is that polyphenol-rich plant compounds can modulate gut serotonin, but the effects are indirect, running through changes in the microbiome rather than direct inhibition of TPH1.

No dietary intervention has been validated in human clinical trials as a reliable way to lower gut serotonin. That said, the animal evidence is consistent enough to suggest that dietary choices matter, and researchers are paying more attention to how specific foods and food-derived compounds interact with the serotonin-producing machinery in the gut.

Physical Triggers You Might Not Expect

Enterochromaffin cells don’t just respond to chemical signals. They are mechanosensitive, meaning physical stretch and pressure in the gut wall trigger serotonin release. Rhythmic mechanical stimulation of enterochromaffin cells activates TPH1 transcription and promotes serotonin secretion.¹² This means that anything causing chronic distension or abnormal motility patterns could be perpetuating a cycle: stretched gut wall triggers more serotonin, more serotonin drives more motility and secretion, and the resulting gas and fluid cause more distension.

This has practical implications. For someone with excess gut serotonin contributing to diarrhea-predominant symptoms, reducing bloating and intestinal distension through smaller meals, addressing bacterial overgrowth if present, or avoiding gas-producing foods could theoretically help break the cycle. It also explains why conditions that alter gut anatomy affect serotonin output. Roux-en-Y gastric bypass surgery, for instance, increases the total number of serotonin-producing enteroendocrine cells in the intestinal segments that now receive direct food contact, largely because those limbs undergo general tissue growth in response to nutrient exposure.¹³

Why Gut Serotonin Matters Beyond the Gut

Gut-derived serotonin doesn’t stay in the gut. It enters the bloodstream, gets picked up by platelets, and circulates throughout the body. One of the more surprising downstream effects involves bone. Gut-derived serotonin can decrease bone mass by acting on receptors on osteoblast precursors, the cells responsible for building new bone.¹⁴ This connection has prompted research into whether inhibiting gut serotonin synthesis could actually serve as a treatment for osteoporosis. Animal studies suggest that blocking gut-derived serotonin increases bone formation through an anabolic mechanism, meaning it stimulates new bone growth rather than just slowing bone loss.¹⁵

This is still pre-clinical work, but it underscores that gut serotonin is not a localized issue. Patients with chronic inflammatory bowel disease, who tend to have elevated gut serotonin, also tend to have lower bone density. Whether reducing gut serotonin would protect their bones remains an open question, but the biological plausibility is there. It also means that if you’re trying to lower gut serotonin for gastrointestinal reasons, you could be getting a secondary benefit for skeletal health.

What Not to Confuse

The biggest misunderstanding in this space is conflating gut serotonin with brain serotonin. They are made by different enzymes (TPH1 in the gut versus TPH2 in the brain), they don’t cross the blood-brain barrier in meaningful amounts, and they serve completely different functions. Reducing gut serotonin with a peripheral TPH1 inhibitor like telotristat does not lower your brain serotonin, and it won’t cause depression or mood changes. Similarly, SSRIs, the antidepressants that increase serotonin availability in the brain, can have gut side effects (nausea, diarrhea) precisely because SERT is expressed in the intestinal mucosa too.⁴ By blocking SERT in the gut, SSRIs can increase local serotonin availability and trigger the very diarrhea and cramping that someone with IBS-D is trying to avoid.

If you’re on an SSRI and struggling with gastrointestinal symptoms, this is worth discussing with your doctor. The solution isn’t necessarily stopping the antidepressant. Sometimes adding a 5-HT3 antagonist or adjusting the timing can manage the gut effects without sacrificing the psychiatric benefit. But understanding that the gut and brain serotonin systems are functionally separate is the first step toward making sense of what feels like contradictory information.

Practical Approaches Ranked by Evidence

Not all strategies for reducing gut serotonin are equally well supported, and it helps to have a realistic picture of where things stand:

TPH1 inhibitors (telotristat): The strongest evidence. Proven to reduce gut serotonin in humans with carcinoid syndrome and in multiple animal models of inflammation. Currently available by prescription for carcinoid syndrome only.
5-HT3 receptor antagonists: Well-established for symptom control in IBS-D. They don’t reduce serotonin levels, but they reliably blunt its effects on motility and pain. Ondansetron is widely available; alosetron is restricted.
Microbiome modulation: Promising in animal models. Specific probiotic strains can shift colonic serotonin downward, and reshaping the microbiome can restore SERT expression. Human trials are limited, and no specific protocol has been standardized.
Dietary protein shifts: Animal data show that protein source affects gut serotonin, with processed meat proteins raising it and soy protein having a different metabolic profile. Translating this to dietary advice for humans remains premature.
Plant polyphenols (quercetin, tea polyphenols): Encouraging pre-clinical results, particularly for quercetin in post-inflammatory IBS models. These compounds likely work through the microbiome rather than directly on the serotonin-producing machinery, and effective doses in humans haven’t been established.
Reducing mechanical triggers: Theoretically sound, since mechanical stretch activates serotonin production, but no clinical trials have tested whether smaller meals or bloating management meaningfully lower gut serotonin in patients.

The strongest path for someone dealing with a clinical condition like carcinoid syndrome or severe IBS-D involves working with a gastroenterologist who can match the approach to the underlying problem. For milder symptoms or general interest in keeping gut serotonin in check, dietary and microbiome strategies are the most accessible levers, even if the evidence is still building.

Gut-Derived Serotonin and the Vagus Nerve

The gut and brain communicate constantly through the vagus nerve, and serotonin plays a role in both directions of that conversation. The presence of food in the digestive tract, signaled through stretch receptors and chemical sensors, gets transmitted via the vagus nerve to brain structures that then modulate the local release of serotonin from enterochromaffin cells. Through its action on smooth muscle, this serotonin promotes peristalsis and keeps digestion moving. This creates a feedback loop: the brain influences gut serotonin release, and gut serotonin in turn sends signals back to the brain through vagal afferents.

This loop is relevant because it means gut serotonin levels aren’t purely a local gut phenomenon. Stress, which activates vagal and sympathetic pathways, can alter enterochromaffin cell activity. Chronic psychological stress has been linked to changes in gut serotonin dynamics in animal models, partly through altered microbiome composition and partly through direct neural signaling. For people trying to reduce gut serotonin, this is a reminder that the problem doesn’t always start in the gut. Stress management, while not a direct serotonin-lowering strategy, may help by reducing the neural drive that keeps enterochromaffin cells overactive.